MedTrace Logo

Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)

NCT01702506 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-12-18

No results posted yet for this study

Summary

Evaluation of the potential effect that the administration of food or antacid medication may have in the oral absorption of dacomitinib relative to the administration of dacomitinib in absence of food or antacid medication

Conditions

  • Healthy Volunteers

Interventions

DRUG

dacomitinib fasted

Overnight fasted subjects will receive a single 45 mg dose of dacomitinib

DRUG

dacomitinib fed

Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal

DRUG

dacomitinib+antacid

Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01702506 on ClinicalTrials.gov